Explore Thymulin dosage trends, reconstitution volumes, and vial size patterns from anonymized WPA peptide calculator sessions.
Thymulin (FTS, facteur thymique sérique) is a zinc-dependent thymic nonapeptide originally isolated by Bach and Dardenne at Hôpital Necker in Paris (1977), studied for its role in T-cell maturation. Its mechanism — zinc binding required for biological activity — and its origin in a French academic program make it mechanistically distinct from the Khavinson short-peptide bioregulator family. This data shows the dose amounts, vial sizes, and diluent volumes researchers most commonly select when reconstituting Thymulin.
Thymulin — originally FTS (facteur thymique sérique) in the French literature — is a zinc-dependent thymic nonapeptide isolated and characterized in 1977 by Jean-François Bach and Mireille Dardenne at Hôpital Necker (Paris). The molecule is mechanistically distinct from every other thymic peptide elsewhere on this site: it is the only thymic peptide whose biological activity is strictly zinc-dependent — the apo (zinc-free) form is inactive, and only the zinc-coordinated holo form binds and signals. Thymulin acts on T-cell precursors to promote maturation and has been extensively characterized in autoimmune, infection, and aging models, with the most-cited body of work coming directly from Bach and Dardenne's laboratory through the late 1970s and 1980s.
Thymulin (FTS) is a zinc-bound nonapeptide thymic hormone studied for immune-modulation research. It ships as a lyophilized powder, and because only the zinc-bound form is active, both peptide identity and the zinc question are worth checking on the certificate of analysis (COA).
Thymulin's biological activity is zinc-dependent: only the zinc-bound nonapeptide is biologically active, and zinc deficiency produces functional thymulin deficiency even when the apopeptide is present. In immune cells, thymulin promotes T-cell differentiation, modulates CD4/CD8 balance, and produces measurable effects on cytokine production through what is currently characterised as conventional cell-surface receptor signalling (the precise receptor identity remains incompletely resolved). The mechanism contrasts sharply with the unreplicated direct-DNA-binding framework proposed by the Khavinson group for thymic short peptides like Thymogen and Vilon.
Beyond Bach's original characterisation in the 1970s and 1980s, thymulin has been studied as an immune-modulator in primary and secondary immunodeficiency, zinc-deficiency states, and (in pre-clinical work) as an anti-inflammatory agent in models of acute lung injury and sepsis. No FDA-approved indication exists, and no Phase 3 trial has demonstrated a clinically meaningful effect in a contemporary immunology indication.
Thymulin has a reported half-life of ~1 hour (estimate), and the dose intervals researchers model most often fall around once daily. This zinc-dependent thymic nonapeptide clears from plasma within hours, with no meaningful buildup between daily doses. Formal human PK data are not established. It is catalogued under Anti-Aging Peptides on WPA.
7 Thymulin reconstitution calculations have been logged by the WPA community. The most common dose entered is 1mg (2 calculations). The most common bacteriostatic water volume is 2mL. The most popular vial size is 10mg (6 sessions). The most common dosing frequency is daily (7x/week) (1 logged protocols).
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.